Anemia is a potential nontraditional risk factor for cardiovascular disease (CVD). This study
evaluated whether anemia is a risk factor for adverse outcomes in people with diabetes and …

Hemoglobin cycling in hemodialysis patients treated with recombinant human
erythropoietin. Background Treatment with recombinant human erythropoietin (rHuEPO) has …

The cytokine erythropoietin (EPO) protects the heart from ischemic injury, in part by
preventing apoptosis. However, EPO administration can also raise the hemoglobin …

Erythropoietin is a hypoxia-induced hormone that is a major regulator of normal
erythropoiesis. Over the last decade, the production of recombinant human erythropoietin …

Erythropoietin (EPO), the principal hematopoietic cytokine produced by the kidney and the
liver in fetuses, regulates mammalian erythropoiesis and exhibits diverse cellular effects in …

Background Friedreich's ataxia (FRDA) is a neurodegenerative disorder caused by
decreased expression of the protein frataxin, recently described to be an iron chaperone for …

Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal
failure and hemoglobin< 10 g/dL. Background Left ventricular hypertrophy (LVH) frequently …

Background: Recombinant human erythropoietin (rhEPO) protects tissue from ischemic
damage, but translation of this finding into useful guidelines with respect to human trials for …

Anaemia is common in patients with congestive heart failure (CHF). Its prevalence increases
with disease severity as a consequence of renal insufficiency, cytokine production, blood …

Another very important factor is the condition of the patient. The myocardium of aged
experimental animals and patients cannot be adequately preconditioned. 6 Exercise, 7 …